Asia Pacific Biosimilars Market Size & Outlook, 2026-2033
Global Market
Related Markets
Asia Pacific biosimilars market highlights
- The Asia Pacific biosimilars market generated a revenue of USD 8,010.0 thousand in 2025.
- The market is expected to grow at a CAGR of 19.8% from 2026 to 2033.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating drug class in 2025.
- Insulin & Analogues is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 8,010.0 thousand |
| Market revenue in 2033 | USD 33,695.2 thousand |
| Growth rate | 19.8% (CAGR from 2026 to 2033) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Insulin & Analogues |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD thousand |
| Market segmentation | Monoclonal Antibodies (mAbs), Growth Factors & Hematopoietic Agents, Insulin & Analogues, Osteoporosis / Bone Metabolism Agents, Others Drug Class |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 20.2% of the global biosimilars market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 33,695.2 thousand by 2033.
Asia Pacific accounted for a major market share in 2019 owing to the growing demand for less expensive therapeutic products and high prevalence of chronic diseases are contributing to the regional market growth. Increasing focus on product developments in countries including China, India, and South Korea is another major factor anticipated to drive the market in this region.
Also, rising urbanization, an increasingly aging population and lifestyle changes in Asia Pacific have also led to the growing incidence of non-communicable diseases such as cancer, diabetes and autoimmune disorders.
South Korea has been more aggressive in the development of biosimilars, also China has been providing generous funding for the development of biotechnology industry which includes biosimilars and an additional USD 11.8 billion was funded for the duration 2015-2020 in order to advance innovations in the biotechnology sector.
No credit card required*
Publish Date: Nov 05, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Dr. Reddy’s Laboratories | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | www.drreddys.com/ |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
| Viatris Inc | View profile | 38,000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | www.viatris.com |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
| Samsung Bioepis | View profile | 501-1000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbioepis.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | www.biocon.com |
Asia Pacific Biosimilars Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biosimilars Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies (Mabs) was the largest segment with a revenue share of 53.11% in 2025.
Horizon Databook has segmented the Asia Pacific biosimilars market based on monoclonal antibodies (mabs), growth factors & hematopoietic agents, insulin & analogues, osteoporosis / bone metabolism agents, others drug class covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific accounted for a major market share in 2019 owing to the growing demand for less expensive therapeutic products and high prevalence of chronic diseases are contributing to the regional market growth. Increasing focus on product developments in countries including China, India, and South Korea is another major factor anticipated to drive the market in this region.
Also, rising urbanization, an increasingly aging population and lifestyle changes in Asia Pacific have also led to the growing incidence of non-communicable diseases such as cancer, diabetes and autoimmune disorders.
South Korea has been more aggressive in the development of biosimilars, also China has been providing generous funding for the development of biotechnology industry which includes biosimilars and an additional USD 11.8 billion was funded for the duration 2015-2020 in order to advance innovations in the biotechnology sector.
- Asia Pacific Biosimilars Market Drug Class Outlook (Revenue, USD Thousand , 2021-2033)
- Monoclonal Antibodies (mAbs)
- Growth Factors & Hematopoietic Agents
- Insulin & Analogues
- Osteoporosis / Bone Metabolism Agents
- Others
- Asia Pacific Biosimilars Market Indication Outlook (Revenue, USD Thousand , 2021-2033)
- Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
- Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
- Diabetes Mellitus (Type 1 & Type 2)
- Ophthalmic Disorders (Wet AMD, DME, RVO)
- Hematologic / Rare Blood Disorders
- Others
- Asia Pacific Biosimilars Market End Use Outlook (Revenue, USD Thousand , 2021-2033)
- Hospitals
- Specialty Pharmacies
- Online & Retail Channels
Reasons to subscribe to Biosimilars Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biosimilars Market Outlook databook
- Our clientele includes a mix of Biosimilars Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Biosimilars Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Biosimilars Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Biosimilars Market, 2021-2033 (US$K)
Asia Pacific biosimilars market statistics, by drug class, 2021-2033 (USD Thousand)
